Results: People with diabetes showed statistically highly significant less loss of axonal super‐excitability in both sensory and motor axons (SupEx isc motor −10.7 % vs. 1.3%, SupEx isch sensory −3.5 % vs. 13.9 %; p < 0.001).
A tendency towards significance was found for differences in age at visit ( p = 0.005).
CD8 + lymphocytes were also increased, although the difference did not reach statistical significance (1608.6 ± 568.6 vs 1391.6 ± 392.3; p = 0.504).
In bulbar‐onset ALS, CST FA showed a trend toward predicting survival but did not reach statistical significance (HR = 0.0008, 95% CI: 4.15 × 10 −7 – 1.46, p = 0.063).
A marginally significant association was observed between changes in pRNFL thickness over time and the appearance of new periventricular lesions.
Tenecteplase showed a numerical trend toward benefit (OR 1.33; 95% CrI 0.98–1.78) but did not reach statistical significance.
Results: Atogepant treatment resulted in a nominally significant higher proportion of participants achieving the ability to think clearly compared with placebo as early as 2‐hours postdose in the first treated attack (OR: 1.78, Figure 1); this effect increased over time through 4‐ and 8‐hours postdose (OR: 3.39, 3.73, respectively; Figure 1).